Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Many safety-related claims (addiction/abuse/misuse, respiratory depression, dependence/withdrawal, and CNS depressant/alcohol caution) are broadly consistent with the label excerpts provided. However, several claims are unsupported or not substantiated by the supplied label text (e.g., specific common side effects listed as sleepiness/dizziness/nausea/constipation, and specific pharmacology mechanisms). Also, indications are described without the label’s specific limitations of use (reserve for patients where alternatives are inadequate and not PRN).
Category Scores
Accurate Statements
With longer-term use, tapentadol carries a dependence and withdrawal risk similar to other opioids.
Supported by 9.3 (tolerance and physical dependence can develop; do not abruptly discontinue; rapid tapering may lead to withdrawal) and 5.14 (Withdrawal).
Tapentadol can cause potential breathing suppression.
Supported by 5.2 (life-threatening/fatal respiratory depression) and 9.2/9.3 cross-references to overdose leading to respiratory depression.
Tapentadol carries the risk of respiratory depression, especially at higher doses or when combined with other sedating drugs.
Partially supported: 5.2 says risk is greatest during initiation or after dosage increase; 5.3 describes profound sedation and respiratory depression with benzodiazepines/other CNS depressants (including alcohol).
Tapentadol requires caution with other central nervous system depressants.
Supported by 5.3 (profound sedation, respiratory depression, coma, death with benzodiazepines and/or other CNS depressants, including alcohol).
Tapentadol requires careful prescribing and monitoring.
Supported by 2.1 (prescribed by knowledgeable healthcare professionals; lowest effective dosage; initiate dosing regimen individually; titration/mitigation of risks) and 5.1 (assess each patient’s risk and reassess).
Tapentadol is available in immediate-release and extended-release formulations.
Not supported by the supplied label excerpts for tapentadol ER tablets. Included here as accurate only if the label excerpts contained it; they do not. Therefore this cannot be considered accurate against the provided text.
Unsupported Statements
Tapentadol is an opioid analgesic used to treat pain.
The provided label excerpts include extensive warnings and dosing instructions for tapentadol ER but do not include the specific indication/usage language for treating pain in the supplied text.
Tapentadol is prescribed for moderate-to-severe pain where an opioid is considered appropriate.
No indication/strength wording (e.g., moderate-to-severe) appears in the supplied label excerpts.
Tapentadol provides opioid receptor (mu) pain relief.
The supplied excerpts do not mention mu-opioid receptor mechanism.
Tapentadol affects norepinephrine signaling in the central nervous system, contributing to its analgesic effect.
The supplied excerpts do not describe mechanism of action (e.g., norepinephrine signaling).
Tapentadol is not the same as tramadol.
No label text provided supports this comparative statement.
Tapentadol is not the same as oxycodone.
No label text provided supports this comparative statement.
Common opioid-related side effects of tapentadol can include sleepiness.
The supplied label excerpts do not list sleepiness as a common adverse reaction.
Common opioid-related side effects of tapentadol can include dizziness.
The supplied label excerpts do not list dizziness as a common adverse reaction.
Common opioid-related side effects of tapentadol can include nausea.
The supplied label excerpts do not list nausea as a common adverse reaction.
Common opioid-related side effects of tapentadol can include constipation.
The supplied label excerpts do not list constipation as a common adverse reaction.
Tapentadol requires careful prescribing and monitoring, particularly in patients with risk factors for opioid complications.
The label excerpts support assessing risk for opioid addiction/abuse/misuse and increased respiratory depression risk in certain populations, but the specific phrase 'risk factors for opioid complications' is not directly supported as written.
Tapentadol is available in immediate-release and extended-release formulations.
The supplied label context is specifically tapentadol extended-release tablets; no label excerpt provided mentions immediate-release formulation availability.
The intended dosing schedule for tapentadol depends on which formulation is prescribed.
The supplied dosing excerpts provide a specific ER regimen but do not explicitly state formulation-dependent scheduling in the label text provided.
Contradictions
Important Omissions
Label limitation of use: reserve tapentadol extended-release tablets for patients for whom alternative treatment options are ineffective, not tolerated, or would be otherwise inadequate; and it is not indicated as-needed (prn) analgesic.
Importance:
Moderate
Crushing/chewing/dissolving instructions: instruct to swallow whole; crushing/chewing/dissolving can result in uncontrolled delivery and overdose/death.
Importance:
Moderate
Naloxone access discussion for emergency treatment of opioid overdose (consider prescribing based on risk factors).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Several safety-related concepts (respiratory depression, dependence/withdrawal, caution with CNS depressants) align with the label excerpts. However, unsupported claims about common adverse effects and mechanism statements could mislead readers about expected side effects or pharmacology. Additionally, omission of label-specific limitation of use (not PRN; reserve for inadequate alternatives), administration instruction (swallow whole), and naloxone access guidance reduces alignment for safe communication.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Moderate |
Recommendation
Partially Aligned
Primary Issue
Multiple claims are unsupported by the provided label excerpts (specific common side effects; receptor/norepinephrine mechanism; comparisons to tramadol/oxycodone; formulation availability for immediate-release; formulation-dependent schedule statement). Indication is also described without label limitations of use (reserve; not PRN).
Suggested Improvement
Restrict claims to those explicitly supported in the provided excerpts (e.g., risks of respiratory depression—greatest during initiation/dose increases; alcohol and CNS depressant co-use warnings; do not abruptly discontinue; not PRN and reserve for inadequate alternatives; swallow ER tablets whole; consider naloxone access). Remove mechanism and formulation-comparison statements unless supported by the label text provided.